Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

Journal of the National Cancer Institute

Volumn 109, Issue 9, 2017, Pages

  Ruers, Theo ^a   Van Coevorden, Frits ^a   Punt, Cornelis J A ^b   Pierie, Jean Pierre E N ^c   Borel Rinkes, Inne ^d   Ledermann, Jonathan A ^e   Poston, Graeme ^f   Bechstein, Wolf ^g   Lentz, Marie Ange ^h   Mauer, Murielle ^h   Folprecht, Gunnar ⁱ   Van Cutsem, Eric ^j   Ducreux, Michel ^k   Nordlinger, Bernard ^l   Paré, Ambroise ^l   Verwaal, V J ^a   Gruenberger, T ^m   Klaase, J ⁿ   Falk, S ^o   Wals, J ^p   Jansen, R L ^q   Lindner P ^r   Mulier, S ^s   Bosscha, K ^t   Jaeck, D ^u   Arnaud, J P ^v   Smith, D ^w   Sherlock, D ^x   Ammori, B ^y   Gillams, A ^e   El Serafi, M ^z   Glimelius, B ^aa   Hellman, P ^ab   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h EORTC DATA CENTER   (Belgium)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ MEDISCH SPECTRUM TWENTE   (Netherlands)

^o BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^p Zuyderland Medical Centre   (Netherlands)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^t JEROEN BOSCH HOSPITAL   (Netherlands)

^u HÔPITAL DE HAUTEPIERRE   (France)

^v ANGERS UNIVERSITY HOSPITAL   (France)

^w CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^x NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^y MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^z NATIONAL CANCER INSTITUTE   (Egypt)

^aa KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ab UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; INTENTION TO TREAT ANALYSIS; LIVER RESECTION; LOCAL THERAPY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CATHETER ABLATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 85017200980     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx015     Document Type: Article

References (28)

1. House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744-752, 752-755.
2. Hackl C, Neumann P, Gerken M, et al. Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.
3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable livermetastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-1215.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677-3683
5. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict longterm survival. Ann Surg. 2004;240(4):644-657; discussion 657-658.
6. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38-47.
7. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075.
8. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563-572.
9. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13):1306-1315.
10. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843-1852.
11. Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241-260.
12. Gervais DA, Goldberg SN, Brown DB, et al. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20(suppl 7):S342-S347.
13. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493-508.
14. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33(1): 11-17.
15. Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;(6):CD006317.
16. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: Factors affecting outcomes-a 10-year experience at a single center. Radiology. 2016;278(2):601-611.
17. Hompes D, Prevoo W, Ruers T. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging. 2011;11:23-30.
18. Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45(10):1748-1756.
19. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10): 2619-2626.
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
21. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
23. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97(8): 1035-1039.
24. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243-9249.
25. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008;62(2):195-201.
26. Saltz L, Badarinath S, Dakhil S et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2012;11(2):101-111.
27. Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO Annual Meeting Abstracts. J Clin Oncol. 2014; 32(18).
28. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-1215.